A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Clinical trial NCT00211068 · COMPLETED
Trial details
- NCT number
- NCT00211068
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2004-03-01
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.